More on PHO
Data
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $65.77 |
|
|||
| Open | $65.94 | ||||
| 52 Wk High | $24.79 | ||||
| 52 Wk Low | $18.15 | ||||
| Day High | $66.29 | ||||
| Day Low | $65.47 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 43,240 | ||||
- Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer
- Photocure acquires Vesica Health for $30.5 million in bladder cancer deal
- Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics
- AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study
- Photocure ASA: Results for the first quarter of 2026
- New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer
- Photocure ASA: Update on Regulatory Classification for OAY Equipment
- Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway
- Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
- Photocure ASA: Results for the fourth quarter of 2025
Entities mentioned with PHO
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Dividend | View Related Stories »
- FDIC | View Related Stories »
- Raising Prices | View Related Stories »
- S3 | View Related Stories »
- Show More...
